Which cancer treatment directions can be assessed?

Treatment or testing process

1. 1.Collect T cells
2. 2.Modify and expand cells
3. 3.Infuse cells and continue monitoring

What the doctor will assess

The hospital checks subtype, targets, previous treatment, infections and organ function against the product information or study protocol. Gastric cancer CLDN18.2 study conditions cannot be applied to other solid tumours.

How to seek care in China

Ask a haematology department, lymphoma center or trial center about the product, collection and manufacture, admission and follow-up requirements. Cell products need a specific basis for access. Lecheng policy cannot replace eligibility for product use.

Available evidence

Approved CAR-T products exist for blood cancers. For example, ciltacabtagene autoleucel is used for relapsed or refractory multiple myeloma meeting approval conditions. CT041-ST-01 is a randomised phase II study in previously treated advanced gastric or gastro-oesophageal junction cancer. Its progression-free survival findings apply only to the enrolled population. Current enrolment must be confirmed by the study center.

Treatment or testing process

1. 1.Tumour samples and sequence analysis
2. 2.Select neoantigens and manufacture
3. 3.Monitor immune and clinical outcomes after vaccination

What the doctor will assess

Sample quality, tumour type, disease stage and study criteria determine manufacture and enrolment. The same mRNA label does not mean the same product.

How to seek care in China

Request the product name and research registration or clinical translational basis from the project institution. Confirm what happens if manufacture fails and the follow-up plan.

Available evidence

In the 2023 Nature phase I pancreatic cancer study, 8 of 16 vaccinated patients had vaccine-induced T-cell responses. This measures immune response, not tumour response or cure rates. Early small studies also cannot directly demonstrate efficacy of other institutions' products.

Treatment or testing process

1. 1.Screen against the study protocol
2. 2.Virus-related treatment and combination medicines
3. 3.Monitor safety and efficacy endpoints

What the doctor will assess

Follow registered and hospital-confirmed inclusion and exclusion criteria, including previous immunotherapy, liver function and general condition. Entering screening does not mean approval for treatment.

How to seek care in China

Check current recruitment, screening location and contacts with registered study institutions. Do not buy investigational medicines through intermediaries. Special-access clinical translation and marketing approval require separate verification.

Available evidence

NCT07589244 registers VRT106 with camrelizumab and apatinib for liver cancer after immunotherapy failure. Registration describes design and status; it is not completed proof of efficacy.

Treatment or testing process

1. 1.Simulation and dose planning
2. 2.Particle beam irradiation of the lesion
3. 3.Review response and normal tissue effects

What the doctor will assess

Assess tumour location, movement, extent and previous radiotherapy dose. Diffuse metastases require systemic consideration; local irradiation cannot be treated as whole-body treatment.

How to seek care in China

Confirm operating equipment, eligible sites, simulation and planning times with the particle treatment center. A large medical equipment configuration licence does not mean an institution has started accepting patients.

Available evidence

Proton dose distribution may reduce irradiation of some normal tissues, but individual clinical benefit needs comparison with photon radiotherapy appropriate to the condition. Heavy ions and protons differ in evidence, equipment and dose models.

Treatment or testing process

1. 1.Assess boron medicine distribution
2. 2.Neutron irradiation
3. 3.Follow up local response and toxicity

What the doctor will assess

Pathological type, site, previous irradiation, organ function and medication conditions all affect eligibility. Failure of other treatments does not establish BNCT suitability.

How to seek care in China

Ask a Lecheng or other center to verify equipment, boron medicine, access documents and indications. Overseas approval cannot replace a Chinese institution's eligibility to use them.

Available evidence

Japan approved relevant BNCT medicines and equipment in 2020 for unresectable head and neck cancer within specified indications. A manufacturer announcement records treatment in Lecheng in 2026. Interpret evidence for each equipment-medicine combination separately. The institution confirms current indications and patient acceptance.

Treatment or testing process

1. 1.Locate the target with ultrasound
2. 2.Mechanical tissue destruction
3. 3.Image the local response

What the doctor will assess

Assess lesion visibility, location and safe treatable extent. Liver device indications cannot be expanded into routine pancreatic, brain or other organ treatment.

How to seek care in China

Confirm equipment and special-access procedures with the Lecheng hospital, and whether existing imaging allows assessment.

Available evidence

The FDA's Edison System K233466 documents describe liver tumour tissue destruction. Device clearance does not demonstrate longer overall survival or suitability for every liver cancer or liver metastasis patient.

Treatment or testing process

1. 1.Check targets and the product
2. 2.Treat within approval conditions
3. 3.Monitor response and toxicity

What the doctor will assess

Tarlatamab relates to small cell lung cancer. Ivonescimab and other medicines each need pathology, test and treatment-line checks. Lung cancer subtypes are not interchangeable.

How to seek care in China

Ask the hospital about routine supply or special-access applications, first-dose observation and inpatient or outpatient arrangements. Historical Lecheng introduction does not mean current use is confined to Lecheng.

Available evidence

The Lecheng platform documents historical introducing institutions, indications and Chinese marketing status for tarlatamab. Current conditions follow nationally approved product information and confirmation by the receiving hospital.

Treatment or testing process

1. 1.Confirm targets and testing
2. 2.Antibody delivery of the payload
3. 3.Monitor organ toxicity and response

What the doctor will assess

Check tumour type, target expression, prior treatment and the product. A positive target does not automatically establish eligibility for every corresponding ADC.

How to seek care in China

The hospital checks Chinese product information, pharmacy supply or research projects. Provide complete pathology biomarker results and previous medicines targeting the same marker in your enquiry.

What to consider when comparing plans

When comparing ADCs, check the study population's cancer, target and prior treatment before reviewing efficacy, follow-up and adverse reactions. Different products' results are not directly interchangeable.

Treatment or testing process

1. 1.Assess pathology and biomarkers
2. 2.Match an applicable regimen
3. 3.Reassess efficacy and adverse reactions

What the doctor will assess

Doctors assess pathology, stage, targets, prior medicines and other conditions. The hospital also decides whether additional molecular testing is needed.

How to seek care in China

Contact the receiving hospital to confirm generic names, testing requirements, supply and medicine continuation at home. Do not stop medicines yourself or directly substitute similar products across countries.

Available evidence

Resistance may require reassessment; targeted treatment and immunotherapy both have eligibility limits. Chinese negotiated insurance prices or study response rates cannot directly serve as international patient quotes or individual prognosis.

Treatment or testing process

1. 1.Assess resectability and anaesthesia
2. 2.Select a suitable surgical approach
3. 3.Pathological confirmation and rehabilitation

What the doctor will assess

Assess tumour extent, previous surgery, health and team experience. Some patients need open surgery or other treatment. Incision size alone should not determine the choice.

How to seek care in China

Ask the relevant cancer surgery department about the procedure, possible conversion to open surgery, pathology reports and subsequent treatment continuity.

What to consider when comparing plans

First clarify whether the operation aims to remove a tumour, establish diagnosis or relieve symptoms. Then compare resection extent, functional effects and recovery for the proposed procedure. A robot is an operating tool; choices still depend on the condition and team experience.

Treatment or testing process

1. 1.Input suitable records
2. 2.Algorithm-assisted analysis
3. 3.Doctor reviews findings alongside the records

What the doctor will assess

Confirm the tool's task, appropriate authorisation and whether its data match your circumstances.

How to seek care in China

The hospital explains the tool's role in this examination, review responsibility and whether standard testing is needed.

Available evidence

NCI uses AI in several areas of cancer research and assisted decision-making. Image models predicting genetic changes cannot be described as replacing tissue or molecular testing. Research accuracy cannot be rewritten as hospital cure rates.

Treatment or testing process

1. 1.Assess symptoms and medicines
2. 2.Select evidence-supported adjunctive measures
3. 3.Reassess effects and interactions

What the doctor will assess

Tell the oncology team about all Chinese medicines, supplements and adjunctive treatments. Acupuncture and similar measures need infection, bleeding and local assessments.

How to seek care in China

Discuss joint support from oncology, pain, nutrition, rehabilitation and traditional Chinese medicine departments through established healthcare institutions.

Available evidence

Studies provide supportive evidence for acupuncture in some cancer-related symptoms. This does not establish tumour elimination or guarantee improved immune function.

Treatment or testing process

1. 1.Disease and donor assessment
2. 2.Conditioning and cell infusion
3. 3.Immune reconstitution and long-term follow-up

What the doctor will assess

Transplant type depends on the disease, response, organ function and available donors. Related donors need independent assessment. Absence of waiting or rejection risk cannot be promised.

How to seek care in China

Confirm records, donor screening, stay requirements and monitoring after returning home with the blood transplant center.

Available evidence

Post-transplant infection, immune recovery and graft-versus-host disease management affect long-term care. Data for different diseases and protocols cannot be combined into one success rate.